SG11201810268YA - Combination therapy with notch and pd-1 or pd-l1 inhibitors - Google Patents

Combination therapy with notch and pd-1 or pd-l1 inhibitors

Info

Publication number
SG11201810268YA
SG11201810268YA SG11201810268YA SG11201810268YA SG11201810268YA SG 11201810268Y A SG11201810268Y A SG 11201810268YA SG 11201810268Y A SG11201810268Y A SG 11201810268YA SG 11201810268Y A SG11201810268Y A SG 11201810268YA SG 11201810268Y A SG11201810268Y A SG 11201810268YA
Authority
SG
Singapore
Prior art keywords
cancer
international
indiana
indianapolis
eli lilly
Prior art date
Application number
SG11201810268YA
Other languages
English (en)
Inventor
Mark Harrath Bender
Hong Gao
Bharvin Kumar Patel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11201810268YA publication Critical patent/SG11201810268YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201810268YA 2016-05-20 2017-05-16 Combination therapy with notch and pd-1 or pd-l1 inhibitors SG11201810268YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662339363P 2016-05-20 2016-05-20
PCT/US2017/032790 WO2017200969A1 (fr) 2016-05-20 2017-05-16 Traitement d'association utilisant des inhibiteurs de notch et de pd-1 ou pd-l1

Publications (1)

Publication Number Publication Date
SG11201810268YA true SG11201810268YA (en) 2018-12-28

Family

ID=58772978

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810268YA SG11201810268YA (en) 2016-05-20 2017-05-16 Combination therapy with notch and pd-1 or pd-l1 inhibitors

Country Status (14)

Country Link
US (2) US10688104B2 (fr)
EP (1) EP3458091B1 (fr)
JP (1) JP7194022B2 (fr)
KR (1) KR102463617B1 (fr)
CN (2) CN109475629A (fr)
AU (1) AU2017268187A1 (fr)
BR (1) BR112018073673A2 (fr)
CA (1) CA3025024A1 (fr)
ES (1) ES2904880T3 (fr)
IL (1) IL263110B (fr)
MA (1) MA45025A (fr)
MX (1) MX2018013941A (fr)
SG (1) SG11201810268YA (fr)
WO (1) WO2017200969A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
MX2018000621A (es) 2015-07-13 2018-05-11 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos.
KR102418766B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
CA3020875A1 (fr) 2016-04-12 2017-10-19 Eli Lilly And Company Traitement d'association a base d'inhibiteurs de notch et de cdk4/6 pour le traitement du cancer
BR112018073673A2 (pt) 2016-05-20 2019-02-26 Eli Lilly And Company terapia de combinação com inibidores de notch e de pd-1 ou pd-l1
WO2018071307A1 (fr) 2016-10-12 2018-04-19 Eli Lilly And Company Traitement ciblé de lymphome à cellules t matures
IL268349B1 (en) 2017-02-17 2024-04-01 Hutchinson Fred Cancer Res Combination therapies for the treatment of BCMA-associated cancer and autoimmune disorders
CN116327957A (zh) * 2017-12-18 2023-06-27 德彪药业国际股份公司 治疗癌症的激动剂抗PD-1抗体与GnRH激动剂或GnRH拮抗剂的组合
CN117729917A (zh) * 2021-04-28 2024-03-19 深圳艾欣达伟医药科技有限公司 使用akr1c3活化化合物与免疫检查点抑制剂的组合疗法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901343T2 (xx) 1996-12-23 1999-09-21 Elan Pharmaceuticals, Inc. Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler.
AU768269B2 (en) 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
GB0303663D0 (en) * 2003-02-18 2003-03-19 Lorantis Ltd Assays and medical treatments
PT2439273T (pt) 2005-05-09 2019-05-13 Ono Pharmaceutical Co Anticorpos monoclonais humanos para morte programada 1 (pd- 1) e métodos para o tratamento de cancro utilizando anticorpos anti-pd-1 isoladamente ou em combinação com outros imunoterapêuticos
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1907432B1 (fr) 2005-07-05 2011-12-07 FUJIFILM Corporation Copolymere et composition polymerisable
DE102006002966A1 (de) * 2006-01-21 2007-07-26 Schaeffler Kg Laufscheibe mit integrierter Wälzkörperlaufbahn
US8633179B2 (en) 2007-03-13 2014-01-21 The Trustees Of Columbia University In The City Of New York Synergistic interaction of NOTCH-1 inhibitors with glucocorticoids
EP2560007A1 (fr) 2007-03-28 2013-02-20 Pharmacyclics, Inc. Identification des Inhibiteurs de la tyrosine kinase de bruton
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EA017286B1 (ru) 2007-08-14 2012-11-30 Эли Лилли Энд Компани Ингибиторы гамма-секретазы
CA2710913A1 (fr) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
EP2350129B1 (fr) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions d'antagonistes de pd-1 et methodes d'utilisation associees
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
US8741295B2 (en) 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
US20120213029A1 (en) 2009-08-26 2012-08-23 Frxsh Ag Apparatus and method for mixing of a material to be mixed
US8637493B2 (en) 2009-11-12 2014-01-28 University Of Massachusetts Methods for treating glioblastoma
RU2571204C3 (ru) 2009-11-24 2020-12-14 Медиммьюн Лимитед Специфические связывающие агенты против в7-н1
CN102085372A (zh) 2009-12-04 2011-06-08 中国医学科学院基础医学研究所 Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途
US9163087B2 (en) * 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
JO3148B1 (ar) * 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
EA036814B9 (ru) 2011-11-28 2021-12-27 Мерк Патент Гмбх Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение
ES2822665T3 (es) * 2013-05-31 2021-05-04 Merck Sharp & Dohme Terapias de combinación para el cáncer
US9698876B2 (en) 2013-07-23 2017-07-04 Telefonaktiebolaget Lm Ericsson (Publ) Transmission mode allocation in LTE networks
US9827309B2 (en) 2013-08-20 2017-11-28 Merck Sharp & Dohme Corp. Treating cancer with a combination of a PD-1 antagonist and dinaciclib
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
WO2015117164A1 (fr) * 2014-02-03 2015-08-06 Memorial Sloan-Kettering Cancer Center Macrophages associés à une tumeur et procédés et compositions pour cibler une thérapie anticancéreuse et identifier des répondeurs potentiels
US10092645B2 (en) * 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
US9914774B2 (en) 2014-07-11 2018-03-13 Genentech, Inc. Notch pathway inhibition
RU2751660C2 (ru) 2014-07-21 2021-07-15 Новартис Аг Лечение злокачественного новообразования с использованием гуманизированного химерного антигенного рецептора против всма
US9465158B2 (en) * 2014-09-04 2016-10-11 National Taiwan Normal University Light-guide coupler for modulating angular and spatial distributions of light source
CN107206071A (zh) * 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
US10828352B2 (en) * 2014-10-27 2020-11-10 Fred Hutchinson Cancer Research Center Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
CA2966042A1 (fr) * 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Therapie combinee pour le traitement d'une maladie
CN113388036A (zh) 2014-12-05 2021-09-14 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的抗体及其用途
WO2016164580A1 (fr) 2015-04-07 2016-10-13 Novartis Ag Thérapie combinée par récepteur antigénique chimérique et dérivés d'amino pyrimidine
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
WO2017019496A1 (fr) 2015-07-24 2017-02-02 Berenson James Richard Modulateurs de la gamma-sécrétase pour le traitement de dysfonctionnement du système immunitaire
CA3020875A1 (fr) 2016-04-12 2017-10-19 Eli Lilly And Company Traitement d'association a base d'inhibiteurs de notch et de cdk4/6 pour le traitement du cancer
KR102418766B1 (ko) 2016-04-12 2022-07-08 일라이 릴리 앤드 캄파니 암 치료에 사용하기 위한 Notch 및 PI3K/mTOR 억제제의 조합 요법
BR112018073673A2 (pt) 2016-05-20 2019-02-26 Eli Lilly And Company terapia de combinação com inibidores de notch e de pd-1 ou pd-l1
CN116473978A (zh) 2016-08-31 2023-07-25 伊莱利利公司 用于治疗实体瘤的给药方案
WO2018071307A1 (fr) 2016-10-12 2018-04-19 Eli Lilly And Company Traitement ciblé de lymphome à cellules t matures
WO2018201056A1 (fr) 2017-04-28 2018-11-01 Novartis Ag Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
MA50564A (fr) 2017-11-06 2020-09-16 Hutchinson Fred Cancer Res Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase

Also Published As

Publication number Publication date
US11826317B2 (en) 2023-11-28
BR112018073673A2 (pt) 2019-02-26
US20220008432A1 (en) 2022-01-13
KR20190008913A (ko) 2019-01-25
CN109475629A (zh) 2019-03-15
AU2017268187A1 (en) 2018-11-29
MA45025A (fr) 2019-03-27
IL263110A (en) 2018-12-31
CA3025024A1 (fr) 2017-11-23
US10688104B2 (en) 2020-06-23
ES2904880T3 (es) 2022-04-06
MX2018013941A (es) 2019-03-21
JP7194022B2 (ja) 2022-12-21
US20190192531A1 (en) 2019-06-27
EP3458091B1 (fr) 2021-11-17
WO2017200969A1 (fr) 2017-11-23
CN115845070A (zh) 2023-03-28
EP3458091A1 (fr) 2019-03-27
JP2019516733A (ja) 2019-06-20
KR102463617B1 (ko) 2022-11-03
IL263110B (en) 2022-07-01

Similar Documents

Publication Publication Date Title
SG11201810268YA (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201804647TA (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201811225RA (en) Ar+ breast cancer treatment methods
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201807965YA (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201811559WA (en) Cancer treatment combinations
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201809162XA (en) 6-aminopyridin-3-yl thiazoles as modulators of ror?t
SG11201810940XA (en) Methods of treating pancreatic cancer
SG11201901389XA (en) Combination therapy with glutaminase inhibitors
SG11201906543RA (en) HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY